{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061558","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.957167+00:00","generated_at":"2026-06-08T07:36:37.810938+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Candel Therapeutics Q3 2023 net loss $8.4M; cash runway into Q2 2024","bullets":["Net loss of $8.4M in Q3 2023, versus $8.7M loss in Q3 2022; no revenue recognized.","Cash and equivalents $43.0M as of Sept 30, 2023; expected to fund operations into Q2 2024.","R&D expenses $5.8M (+7.4% YoY) driven by CAN-2409 manufacturing and regulatory work.","G&A expenses $3.0M (-14.3% YoY) due to lower professional service and consulting costs.","Topline overall survival data for CAN-2409 in NSCLC expected Q2 2024; prostate cancer data in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061558","json":"https://secwatch.observer/filing/0000950170-23-061558.json","markdown":"https://secwatch.observer/filing/0000950170-23-061558.md","text":"https://secwatch.observer/filing/0000950170-23-061558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023061558/0000950170-23-061558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023061558/cadl-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:36:37.810938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2690903a2e1a731f0abed89c4492f3552a37246","claim":"Candel Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023061558/0000950170-23-061558-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}